MedElevator Войти в исследования
← Поиск публикаций

DOI 10.15326/jcopdf.2026.0804

Медицинская библиотека · Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026

Comparison of Nebulized Long-Acting Muscarinic Antagonist Revefenacin to Ipratropium in COPD Patients With Acute Respiratory Failure Requiring Mechanical Ventilation: Results of the RARICO Study.

Barjaktarevic Igor, Dartt Matthew, Chen Siyan, Champion D'Mitri, Mempin Roberto, Dejsatha Yongyus, Van Vleet Joseph, Chang Steven, Estrada Oscar, Young Timothy, Buhr Russell, Tashkin Donald, Bando Joanne M

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Revefenacin is a nebulized long-acting muscarinic antagonist approved for maintenance therapy in stable chronic obstructive pulmonary disease (COPD). We conducted a pilot study to evaluate the feasibility and safety of revefenacin in mechanically ventilated COPD patients with acute respiratory failure (ARF), and compare its use with the short-acting muscarinic antagonist ipratropium, the current standard inpatient therapy.

METHODS

In this double-blind, randomized controlled pilot study, intubated COPD patients were assigned to revefenacin 175mcg once daily plus three placebo doses, or ipratropium 500mcg via vibrating mesh nebulizer every 6 hours, for up to 7 days. The primary endpoints were safety and feasibility; exploratory endpoints included ventilator-derived respiratory mechanics and clinical outcomes.

RESULTS

Twenty-one patients (mean age 76±11 years, 60±51 pack years smoking, percent-predicted FEV1 56±26%) were randomized to revefenacin (N=12) or ipratropium (N=9). Duration of mechanical ventilation was similar between groups (2.5±2.3 vs 3.6±2.8 days; P=0.83), with similar number of administered doses (2.8±2.1 vs 14.2±11.1; P=0.74). Daily nebulization time was significantly lower with revefenacin (7.2±1.0 vs 26.8±5.3 minutes; P<0.01). Adverse events were infrequent and comparable between the groups. Revefenacin improved dynamic resistance (Rdyn) post-dose (-0.9 vs +2.6 cmH₂O/L/s; P<0.01), without differences in peak inspiratory, resistive, or plateau pressures.

CONCLUSION

Once-daily nebulized revefenacin is a feasible and safe alternative to ipratropium in mechanically ventilated COPD patients with ARF, with reduced time spent on nebulization adminitration. Improvements in airway resistance suggest a potential physiologic benefit, warranting further investigation.

Для цитирования: Barjaktarevic Igor, Dartt Matthew, Chen Siyan, Champion D'Mitri, Mempin Roberto, Dejsatha Yongyus, Van Vleet Joseph, Chang Steven, Estrada Oscar, Young Timothy, Buhr Russell, Tashkin Donald, Bando Joanne M. Comparison of Nebulized Long-Acting Muscarinic Antagonist Revefenacin to Ipratropium in COPD Patients With Acute Respiratory Failure Requiring Mechanical Ventilation: Results of the RARICO Study.. Chronic obstructive pulmonary diseases (Miami, Fla.). 2026. DOI: 10.15326/jcopdf.2026.0804.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.